|
|
Sold Out
Book Categories |
PART I: INTRODUCTION.
The Drug Discovery Process.
Clinical Trials, Overview.
Therapeutic Area Trends in R&D of the Top 20 Pharmaceutical Companies.
PART II: ONCOLOGY.
Aggressive Non-Hodgkin's Lymphomas.
Bladder Cancer.
Breast Cancer.
Cervical Cancer.
Chronic Lymphocytic Leukemia (CLL).
Chronic Myelogenous Leukemia.
Colorectal Cancer.
Malignant Melanoma.
Multiple Myeloma.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 2.
PART II: ONCOLOGY.
Non-Small-Cell Lung Cancer.
Ovarian Cancer.
Pancreatic Cancer.
Prostate Cancer.
Small-Cell Lung Cancer.
PART III: IMMUNE SYSTEM.
Allergic Rhinitis.
Asthma.
Crohn's Disease.
Psoriasis.
Rheumatoid Arthritis.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 3.
PART IV. METABOLIC DISEASES.
Diabetic Retinopathy.
Dyslipidemia.
Metabolic Syndrome.
Obesity.
Osteoporosis.
Type 1 Diabetes.
Type 2 Diabetes.
PART V. INFECTIOUS DISEASES.
Acute Exacerbations of Chronic Bronchitis.
Community-Acquired Pneumonia.
Complicated Skin and Soft Tissue Infections.
Hepatitis C.
Methicillin-Resistant Staphylococcus Aureus.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 4.
PART VI. EMERGING TECHNOLOGIES AND BUSINESS OPPORTUNITIES.
Data and Information Integration in Pharmaceutical R&D.
Impact of Technological Advances on Pharmaceutical Productivity.
Advances in Medicinal Chemistry and Lead Optimization.
Bio-Defense Opportunities in the Biotechnology and Pharmaceutical Industries.
Fear of Theranostics: Why an Industry Has Not Really Emerged.
Beyond Commodity Drugs: Strategic Diversification in the Generics Industry.
PART VII: GLOBAL MARKETS AND NATIONAL POLICY.
The EU Clinical Trials Directive: Impact in Europe and Beyond.
The Indian Pharmaceutical Industry in Transition: Changes and Opportunities Ahead.
Spotlight on the Australian and New Zealand Pharmaceutical and Biotechnology Industries.
Overview of the World's Major OTC Markets.
Biotech Hubs-Key Growth Engines for Drug Development.
Pharmaceutical Marketplace in Central and Eastern Europe.
Valuation Models for European Biotech.
Taking Global Action: Integrating Social Responsibility into Corporate Practices.
Global Branding Strategy: From the Blockbuster to the Targeted Model.
PART VIII: NEW OPPORTUNITIES IN DRUG DISCOVERY AND PIPELINE DEVELOPMENT.
Prospects for Genomics-Derived Drugs: New Approaches and Impact on Pharmaceutical Pipelines.
Prying Open the Pipeline: Drug Discovery and Development in the Postgenomics Era.
Glycomics: The Impact of Carbohydrates on Biological Function and the Implications for Drug Discovery.
High-Content Screening for Drug Discovery and Target Validation.
High-Throughput ADMET Screening: Improving the Efficiency of Drug Discovery.
Emerging Concepts in GPCR Research and Their Implications for Drug Discovery.
Optimizing Knowledge Management in Pharmaceutical Companies.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Cumulative Subject Index, Volumes 1-4.
| Price | Condition | Delivery | Seller | Action |
| $99.99 | Digital |
| WonderClub |
Mark Canfield
reviewed Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set on April 02, 2016
Wiley Handbook of Current and Emerging Drug Therapies
I'll be so mad if I don't end up citing this book at least 20 times.
As the other reviewer said, this is a technical book. It probably won't even fall into your hands unless you are deep in a university library somewhere.
My supervisor recommended this book as general reading around my topic, and yup, extensive notes were taken. While I can't say that I've read and digested every word of every argument, it appears to be very thorough and more elaborated than similar texts from the dual-systems/processes/types/minds (because consistent terminology is for pussies) theory side of things.
The clear structuring into chapters-> sections-> subsections is also extremely helpful, as are internal references to previous/following sections of the book for more extensive argumentation of some topics. Idk, may be this is just good practice in academic texts, but I haven't seen this done this clearly before, so I'm impressed.
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish List
X
This item is in your Collection
Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set
X
This Item is in Your Inventory
Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set
X
You must be logged in to review the productsX
X
X
Add Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set, , Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set to the inventory that you are selling on WonderClubX
X
Add Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set, , Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set to your collection on WonderClub |
